Blog
RSS FeedPosted by Michael Wonder on 28 Feb 2026
Highlights from the 23-26 February 2026 CHMP meeting
27 February 2026 - The EMA’s CHMP has recommended 12 medicines for approval at its February 2026 meeting. ...
Posted by Michael Wonder on 27 Feb 2026
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
27 February 2026 - Eli Lilly and Incyte announced today that the EMA's CHMP has issued a positive opinion for Olumiant ...
Posted by Michael Wonder on 27 Feb 2026
Dupixent (dupilumab) recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
27 February 2026 - Regeneron Pharmaceuticals and Sanofi today announced that the EMA’s CHMP adopted a positive opinion recommending the approval ...
Posted by Michael Wonder on 27 Feb 2026
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria
27 February 2026 - Novartis announced today that the CHMP of the EMA has adopted a positive opinion recommending marketing authorisation ...
Posted by Michael Wonder on 26 Feb 2026
Clinical equivalence and non-inferiority within health technology assessment
23 February 2026 - Non-inferiority and clinical equivalence clinical trials can be used to determine whether a health technology is no ...
Posted by Michael Wonder on 24 Feb 2026
First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people
24 February 2026 - For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating ...
Posted by Michael Wonder on 23 Feb 2026
EMA publishes agenda for 23-26 February 2026 CHMP meeting
23 February 2026 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 21 Feb 2026
Do children get priority in Australia's drug funding decisions?
20 February 2026 - In Australia, the PBAC recommends which medicines should be subsidised through the PBS. ...
Posted by Michael Wonder on 21 Feb 2026
Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
19 February 2026 - Lecanemab, also known as Leqembi, is approved to treat mild cognitive impairment, early Alzheimer's. ...
Posted by Michael Wonder on 18 Feb 2026
NICE recommends first ever disease modifying treatment for ARG1 deficiency
17 February 2026 - NICE has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and ...
Posted by Michael Wonder on 12 Feb 2026
ICER publishes final evidence report on medication for smoking cessation
12 February 2026 - Independent appraisal committee votes reflect a net health benefit for cytisinicline alone, but uncertainty when compared ...
Posted by Michael Wonder on 12 Feb 2026
Agenda for the March 2026 PBAC meeting (12 February 2026)
12 February 2026 - The Department of Health has published an updated agenda for the March 2026 PBAC agenda (version 5). ...
Posted by Michael Wonder on 09 Feb 2026
SMC - February 2026 decisions
9 February 2026 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 09 Feb 2026
ICER releases evidence report on therapies for IgA nephropathy
9 February 2026 - All three therapies exhibit net health benefits, but uncertainties remain around the magnitude of long-term improvements ...
Posted by Michael Wonder on 09 Feb 2026
Agenda for the March 2026 PBAC meeting (9 February 2026)
9 February 2026 - The Department of Health has published an updated agenda for the March 2026 PBAC agenda (version ...